株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細胞のリプログラミング (iPS細胞生成) / ダイレクトリプログラミングサービス・製品市場:2020年~2030年

Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030

発行 ROOTS ANALYSIS 商品コード 933277
出版日 ページ情報 英文 293 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.69円で換算しております。
細胞のリプログラミング (iPS細胞生成) / ダイレクトリプログラミングサービス・製品市場:2020年~2030年 Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030
出版日: 2020年03月31日 ページ情報: 英文 293 Pages
概要

当レポートでは、さまざまな慢性疾患の治療における細胞のリプログラミングサービス・製品市場について調査分析し、現在の市場状況と将来の機会について、体系的な情報を提供しています。

考察の例

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 現在の市場情勢

  • 章の概要
  • 細胞のリプログラミングサービス・製品プロバイダー:業界企業のリスト
    • 分析:設立年別
    • 分析:企業規模別
    • 分析:地理的位置別
    • 分析:製造施設の立地別
    • 分析:サービスのタイプ別
    • 分析:提供のタイプ別
    • 分析:技術のタイプ別
    • 分析:使用ベクター別
    • 分析:iPS細胞生成の細胞源別
    • 分析:標的適応別
    • 分析:適応別
    • 分析:付加サービス別
  • 細胞のリプログラミングサービス・製品プロバイダー:非業界企業のリスト
    • 分析:地理的位置別
    • 分析:使用する技術のタイプ別
    • 分析:使用するベクターのタイプ別
    • 分析:iPS細胞生成の細胞源別
  • 細胞のリプログラミング:関連製品プロバイダーのリスト

第5章 企業の競合分析

  • 章の概要
  • 前提条件と主要パラメーター
  • 調査手法
  • 競合分析:iPS細胞生成サービス・製品プロバイダー
  • 競合分析:ダイレクトリプログラミングサービス・製品プロバイダー

第6章 企業プロファイル

  • 章の概要
  • Allele Biotechnology
  • ALSTEM
  • Applied Biological Materials
  • Axol Bioscience
  • Creative Bioarray
  • DefiniGEN
  • FUJIFILM Cellular Dynamics International
  • Lonza
  • Mogrify
  • REPROCELL
  • Stemnovate
  • Thermo fisher Scientific

第7章 ケーススタディ:幹細胞療法の開発における臨床試験活動

  • 章の概要
  • 調査範囲と手法
  • 幹細胞療法:臨床試験分析
    • 分析:試験登録年別
    • 分析:試験フェーズ別
    • 分析:登録された患者数別、試験登録年別
    • 分析:研究設計別
    • 分析:試験募集状況別
    • 分析:スポンサー/コラボレーター別
    • 主要業界スポンサー - 分析:登録された試験数別
    • 分析:試験フォーカス別
    • 分析:幹細胞のタイプ別
    • 分析:治療領域別
    • 分析:幹細胞のタイプ別、治療領域別
    • 地域別分析:臨床試験数別
    • 地域別分析:試験募集状況別
    • 地域別分析:登録された患者集団別

第8章 パートナーシップとコラボレーション

  • 章の概要
  • 調査範囲と手法
  • 細胞のリプログラミングサービス・製品市場:パートナーシップとコラボレーションのリスト

第9章 可能性のあるパートナーシップの機会

  • 章の概要
  • 調査範囲と手法
  • スコアリング基準と主な前提条件
  • 幹細胞療法の開発者:細胞のリプログラミングサービス・製品プロバイダーの有望パートナー
  • 幹細胞療法の受託製造業者:細胞のリプログラミングサービス・製品プロバイダーの有望パートナー

第10章 市場予測

  • 章の概要
  • 調査範囲と手法
  • 予測手法と主な前提条件
  • 世界の細胞のリプログラミングサービス・製品市場

第11章 エグゼクティブ考察

第12章 結論

第13章 付録1:表形式データ

第14章 付録2:企業・組織のリスト

図表

List Of Figures

  • Figure 3.1 Cellular Lineages used for Isolation of Stem Cells
  • Figure 3.2 Steps Involved in the Development and Administration of Stem Cells
  • Figure 3.3 Classification of Stem Cells
  • Figure 3.4 Classification based on Source of Stem Cell
  • Figure 3.5 Differences between Allogeneic and Autologous Stem Cell Therapies
  • Figure 3.6 Classification of Stem Cells based on Origin
  • Figure 3.7 Classification of Adult Stem Cells
  • Figure 3.8 Classification based on Potency of Stem Cell
  • Figure 3.9 Key Application Areas for Stem Cell Therapies
  • Figure 3.10 Potential Applications of Cell Reprogramming
  • Figure 3.11 Key Growth Drivers and Constraints to Cell Reprogramming
  • Figure 4.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
  • Figure 4.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
  • Figure 4.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
  • Figure 4.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
  • Figure 4.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
  • Figure 4.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
  • Figure 4.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
  • Figure 4.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
  • Figure 4.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
  • Figure 4.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
  • Figure 4.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation and Company size
  • Figure 4.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
  • Figure 4.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Directly Reprogrammed cells
  • Figure 4.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
  • Figure 4.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
  • Figure 4.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
  • Figure 4.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
  • Figure 4.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
  • Figure 4.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
  • Figure 5.1 Competitiveness Analysis of iPSCs Generation Service and Product Providers
  • Figure 5.2 Competitiveness Analysis of Direct Reprogramming Service and Product Providers
  • Figure 7.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 7.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Trial Registration Year, 2011-2019
  • Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.7 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 7.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.9 Clinical Trial Analysis: Leading Industry Players
  • Figure 7.10 Clinical Trial Analysis: Distribution by Focus Area
  • Figure 7.11 Clinical Trial Analysis: Distribution by Type of Stem Cell
  • Figure 7.12 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
  • Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
  • Figure 7.15 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
  • Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
  • Figure 7.17 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
  • Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
  • Figure 7.20 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Stem Cell
  • Figure 8.6 Partnerships and Collaborations: Distribution by Target Therapeutic Area
  • Figure 8.7 Partnerships and Collaborations: Distribution by Application
  • Figure 8.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.9 Partnerships and Collaborations: Regional Analysis
  • Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreement
  • Figure 10.1 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
  • Figure 10.2 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
  • Figure 10.3 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
  • Figure 10.4 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
  • Figure 10.5 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
  • Figure 10.6 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
  • Figure 10.7 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
  • Figure 10.8 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
  • Figure 10.9 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
  • Figure 10.10 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
  • Figure 10.11 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
  • Figure 10.12 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
  • Figure 10.13 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
  • Figure 10.14 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
  • Figure 10.15 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
  • Figure 10.16 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
  • Figure 10.17 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
  • Figure 10.18 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

List Of Tables

  • Table 3.1 Differences between Stem Cell Therapies and Other Biologics
  • Table 4.1 Cell Reprogramming Services and Products: List of Industry Players
  • Table 4.2 Cell Reprogramming Services and Products: List of Non-Industry Players
  • Table 4.3 Cell Reprogramming Services and Products: List of Affiliated Product Providers
  • Table 6.1 Cell Reprogramming Service and Product Providers: List of Profiled Companies
  • Table 6.2 ALSTEM: Company Snapshot
  • Table 6.3 ALSTEM: Recent Developments and Future Outlook
  • Table 6.4 Applied Biological Materials: Company Snapshot
  • Table 6.5 Applied Biological Materials: Recent Developments and Future Outlook
  • Table 6.6 Axol Bioscience: Company Snapshot
  • Table 6.7 Axol Bioscience: Recent Developments and Future Outlook
  • Table 6.8 Creative Bioarray: Company Snapshot
  • Table 6.9 Creative Bioarray: Recent Developments and Future Outlook
  • Table 6.10 DefiniGEN: Company Snapshot
  • Table 6.11 DefiniGEN: Recent Developments and Future Outlook
  • Table 6.12 FUJIFILM Cellular Dynamics International: Company Snapshot
  • Table 6.13 FUJIFILM Cellular Dynamics International: Recent Developments and Future Outlook
  • Table 6.14 Lonza: Company Snapshot
  • Table 6.15 Lonza: Recent Developments and Future Outlook
  • Table 6.16 Mogrify: Company Snapshot
  • Table 6.17 Mogrify: Recent Developments and Future Outlook
  • Table 6.18 REPROCELL: Company Snapshot
  • Table 6.19 REPROCELL: Recent Developments and Future Outlook
  • Table 6.20 Stemnovate: Company Snapshot
  • Table 6.21 Stemnovate: Recent Developments and Future Outlook
  • Table 6.22 Thermo Fisher Scientific: Company Snapshot
  • Table 6.23 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 7.1 Cell Reprogramming Services: List of Partnerships and Collaborations
  • Table 9.1 Likely Partners for Cell Reprogramming Service and Product Providers in North America
  • Table 9.2 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
  • Table 9.3 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • Table 9.4 Likely Partners for Cell Reprogramming Service and Product Providers in North America
  • Table 9.5 Likely Partners for Cell Reprogramming Service and Product Providers in Europe
  • Table 9.6 Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • Table 11.1 Asgard Therapeutics: Company Snapshot
  • Table 11.2 Phenocell: Company Snapshot
  • Table 13.1 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Year of Establishment
  • Table 13.2 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Company Size
  • Table 13.3 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Geographical Location
  • Table 13.4 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Location of Manufacturing Facilities
  • Table 13.5 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Service
  • Table 13.6 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Offering
  • Table 13.7 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology
  • Table 13.8 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Technology and Year of Establishment
  • Table 13.9 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Vector Used
  • Table 13.10 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Source Cell for iPSC Generation
  • Table 13.11 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Source Cell for iPSC Generation and company size
  • Table 13.12 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Target Indication
  • Table 13.13 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of directly reprogrammed cell
  • Table 13.14 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Application
  • Table 13.15 Cell Reprogramming Service and Product Providers (Industry Players): Distribution by Type of Additional Service(s) Offered
  • Table 13.16 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Geographical Location
  • Table 13.17 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Technology
  • Table 13.18 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Type of Vector Used
  • Table 13.19 Cell Reprogramming Service and Product Providers (Non-Industry Players): Distribution by Source Cell for iPSC Generation
  • Table 13.20 Clinical Trial Analysis: Distribution by Trial Status
  • Table 13.21 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2019
  • Table 13.22 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 13.23 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, 2011-2019
  • Table 13.24 Clinical Trial Analysis: Distribution by Study Design
  • Table 13.25 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 13.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 13.27 Clinical Trial Analysis: Leading Industry Players
  • Table 13.28 Clinical Trial Analysis: Analysis by Type of Stem Cell
  • Table 13.29 Clinical Trial Analysis: Cumulative Distribution by Type of Stem Cell and Trial Registration Year
  • Table 13.30 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 13.31 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
  • Table 13.32 Clinical Trial Analysis: Distribution by Patient Enrollment and Therapeutic Area
  • Table 13.33 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollment (in thousands) for Popular Therapeutic Areas
  • Table 13.34 Clinical Trial Analysis: Distribution by Type of Stem Cell and Therapeutic Area
  • Table 13.35 Clinical Trial Analysis: Geographical Distribution by Number of Trials
  • Table 13.36 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
  • Table 13.37 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient
  • Table 13.38 Partnerships and Collaborations: Analysis by Year of Partnership
  • Table 13.39 Partnerships and Collaborations: Analysis by Type of Partnership
  • Table 13.40 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
  • Table 13.41 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
  • Table 13.42 Partnerships and Collaborations: Analysis by Type of Stem Cell
  • Table 13.43 Partnerships and Collaborations: Analysis by Target Therapeutic Area
  • Table 13.44 Partnerships and Collaborations: Analysis by Application
  • Table 13.45 Most Active Players: Distribution by Number of Partnerships
  • Table 13.46 Partnerships and Collaborations: Regional Analysis
  • Table 13.47 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 13.48 Global Cell Reprogramming Services and Products Market, 2020-2030 (USD Million)
  • Table 13.49 Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
  • Table 13.50 Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030 (USD Million)
  • Table 13.51 Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030 (USD Million)
  • Table 13.52 Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030 (USD Million)
  • Table 13.53 Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030 (USD Million)
  • Table 13.54 Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
  • Table 13.55 Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030 (USD Million)
  • Table 13.56 Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030 (USD Million)
  • Table 13.57 Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030 (USD Million)
  • Table 13.58 Cell Reprogramming Services and Products Market for Other Cells, 2020-2030 (USD Million)
  • Table 13.59 Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
  • Table 13.60 Cell Reprogramming Services and Products Market for Research, 2020-2030 (USD Million)
  • Table 13.61 Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030 (USD Million)
  • Table 13.62 Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
  • Table 13.63 Cell Reprogramming Services and Products Market in North America, 2020-2030 (USD Million)
  • Table 13.64 Cell Reprogramming Services and Products Market in Europe, 2020-2030 (USD Million)
  • Table 13.65 Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. AA Partners (Ilaya)
  • 3. Abcam
  • 4. ACEA Biosciences
  • 5. Addgene
  • 6. Aegle Therapeutics
  • 7. Allele Biotechnology
  • 8. Alpine BioTherapeutics
  • 9. ALSTEM
  • 10. Altaco XXI
  • 11. American CryoStem
  • 12. Amgen
  • 13. AMS Biotechnology
  • 14. Angel Biotechnology
  • 15. Angiocrine Bioscience
  • 16. Anterogen
  • 17. apceth Biopharma
  • 18. Applied Biological Materials
  • 19. Applied StemCell
  • 20. Asahi Glass
  • 21. Asgard Therapeutics
  • 22. Aspire Health Science
  • 23. Astellas Pharma
  • 24. Athersys
  • 25. Atlantic Bio GMP
  • 26. Axcelead Drug Discovery Partners
  • 27. Axiogenesis
  • 28. Axis Biotec Brasil
  • 29. Axol Bioscience
  • 30. Azidus
  • 31. Bayer
  • 32. Baylx
  • 33. BC Children's Hospital Research Institute
  • 34. Berlin Institute of Health
  • 35. BHI Therapeutic Sciences
  • 36. Bio Elpida
  • 37. BioCardia
  • 38. Biocenter Finland
  • 39. BioGenCell
  • 40. Bioinova sro
  • 41. BioLamina
  • 42. Biological Industries
  • 43. Bioneer
  • 44. BioNTech IMFS
  • 45. Bioquark
  • 46. BioreclamationIVT
  • 47. BioRestorative Therapies
  • 48. Bit Bio
  • 49. Blood Reprogramming Technologies
  • 50. BlueRock Therapeutics
  • 51. Bone Therapeutics
  • 52. BrainStorm Cell Therapeutics
  • 53. Brigham and Women's Hospital
  • 54. Broad Institute
  • 55. Bukwang Pharmaceutical
  • 56. Caladrius Biosciences
  • 57. Cancer Genetics
  • 58. Capricor Therapeutics
  • 59. CAR-T (Shanghai) Biotechnology
  • 60. Cedars-Sinai
  • 61. Celgene
  • 62. Celixir
  • 63. Cell and Gene Therapy Catapult
  • 64. Cell Applications
  • 65. Cell Reprogramming & Therapeutics
  • 66. Cell Signaling Technology
  • 67. Cell Tech Pharmed
  • 68. Cell Therapies
  • 69. Cellaria Biosciences
  • 70. Cellerant Therapeutics
  • 71. CELLforCURE
  • 72. CellProthera
  • 73. Cellular Biomedicine Group
  • 74. Cellular Engineering Technologies
  • 75. Cellular Reprogramming
  • 76. Censo Biotechnologies
  • 77. Center for iPS Cell Research and Application, Kyoto University
  • 78. Center for Molecular Medicine, Karolinska University Hospital
  • 79. Center for Regenerative Therapies, German Research Foundation
  • 80. CENTOGENE
  • 81. Cesca Therapeutics
  • 82. CHA Biolab
  • 83. Chabiotech
  • 84. Charles River
  • 85. Chiesi Farmaceutici
  • 86. China Regenerative Medicine International
  • 87. Cincinnati Children's Hospital Medical Center
  • 88. Cleans Cells
  • 89. Cognate BioServices
  • 90. Columbia Stem Cell Initiative
  • 91. Cook MyoSite
  • 92. Corestem
  • 93. Creative Bioarray
  • 94. Creative Biolabs
  • 95. Cryosite
  • 96. CureCell
  • 97. Cynata Therapeutics
  • 98. Cytopeutics
  • 99. DefiniGEN
  • 100. DiscGenics
  • 101. Editas Medicine
  • 102. EHL Bio
  • 103. EpiBone
  • 104. Escape Therapeutics
  • 105. ESI BIO
  • 106. European Bank for induced pluripotent Stem Cells
  • 107. European Institute for the Biology of Ageing
  • 108. Ever Supreme Bio technology
  • 109. Evercyte
  • 110. Evotec
  • 111. Evotec
  • 112. Fate Therapeutics
  • 113. Feinberg School of Medicine
  • 114. Ferrer Internacional
  • 115. Fibrocell Science
  • 116. Fortuna Fix
  • 117. FUJIFILM Cellular Dynamics
  • 118. Gamida Cell
  • 119. GE Healthcare
  • 120. GenCure
  • 121. GeneCopoeia
  • 122. Genenta Science
  • 123. Genome Engineering and iPSC Center
  • 124. German Stem Cell Research Network
  • 125. GlaxoSmithKline
  • 126. Global Cell Med
  • 127. Gwo xi Stem Cell
  • 128. Harvard Stem Cell Institute
  • 129. Harvard University Stem Cell Institute
  • 130. Hemogenyx
  • 131. Hemostemix
  • 132. Histocell
  • 133. Hitachi Chemical
  • 134. Hope Biosciences
  • 135. Hubei Hongyuan Pharmaceutical technology
  • 136. Human Pluripotent Stem Cell Core Facility
  • 137. Icahn School of Medicine
  • 138. ID Pharma
  • 139. Indiana University
  • 140. Indiana University Research and Technology
  • 141. InSphero
  • 142. Institute of Molecular Biotechnology (IMBA)
  • 143. Institute of Molecular Biotechnology, Austrian Academy of Sceinces
  • 144. International Stem Cell Corporation
  • 145. iPS Academia Japan
  • 146. iXCells Biotechnologies
  • 147. Japan Regenerative Medicine
  • 148. Japan Tissue Engineering
  • 149. Japan Tissue Engineering (J-TEC)
  • 150. jCyte
  • 151. Kadimastem
  • 152. Kangstem Biotech
  • 153. KBI Biopharma
  • 154. Kemwell Biopharma
  • 155. KLSMC Stem Cells
  • 156. K-Stem Cell
  • 157. LAI International
  • 158. Leiden University Medical Center
  • 159. Life & Brain
  • 160. LifeCell
  • 161. Lineage Cell Therapeutics
  • 162. Longeveron
  • 163. Lonza
  • 164. Magellan Stem Cells
  • 165. Magenta Therapeutics
  • 166. MangoGen Pharma
  • 167. MaSTherCell
  • 168. McEwen Stem Cell Institute
  • 169. Med Cell Bahamas
  • 170. Medeor Therapeutics
  • 171. Medicines Discovery Catapult
  • 172. MEDINET
  • 173. Medipost
  • 174. Melbourne Stem Cell Centre
  • 175. Memorial Sloan Kettering Cancer Center
  • 176. Merck
  • 177. Meridigen Biotech
  • 178. Mesoblast
  • 179. Metrion Biosciences
  • 180. MilliporeSigma
  • 181. Miltenyi Biotec
  • 182. Minovia Therapeutics
  • 183. Mogrify
  • 184. National Eye Institute
  • 185. Nature Cell
  • 186. Ncardia
  • 187. Ncardia
  • 188. NeuCyte
  • 189. NeuroGeneration
  • 190. New York Blood Center
  • 191. Newcastle University
  • 192. Newcells Biotech
  • 193. NextCell Pharma
  • 194. Nikon CeLL innovation
  • 195. Nipro
  • 196. Nohla Therapeutics
  • 197. Noray Biosciences Group
  • 198. Novadip Biosciences
  • 199. Novartis Pharmaceuticals
  • 200. NuVasive
  • 201. ONO Pharmaceutical
  • 202. Orchard Therapeutics
  • 203. Orgenesis
  • 204. Orthofix
  • 205. Osiris Therapeutics
  • 206. Oslo University Hospital
  • 207. Ottawa Hospital Research Institute
  • 208. Penn's Institute for Regenerative Medicine
  • 209. Personalized Stem Cells
  • 210. Pharmicell
  • 211. Phenocell
  • 212. Pluriomics
  • 213. Pluristem Therapeutics
  • 214. Plus Therapeutics
  • 215. Promethera Biosciences
  • 216. Propagenix
  • 217. Protide Pharmaceuticals
  • 218. Provia Labs
  • 219. Q Therapeutics
  • 220. R3 Stem Cell
  • 221. Radboudumc Stem Cell Technology Center
  • 222. R-Bio
  • 223. Regeneus
  • 224. Regenexx
  • 225. Reliance Life Sciences
  • 226. ReNeuron
  • 227. ReproCell
  • 228. RheinCell Therapeutics
  • 229. Riordan Technologies
  • 230. Rockland Immunochemicals
  • 231. ROHTO Pharmaceutical
  • 232. Roslin Cells
  • 233. RTI Surgical
  • 234. S.Biomedics
  • 235. Salvat
  • 236. Samsung BioLogics
  • 237. SanBio
  • 238. Sanofi
  • 239. Sanquin
  • 240. SBH Sciences
  • 241. Sclnow Biotechnology
  • 242. SCM Lifescience
  • 243. SCM Lifescience
  • 244. Seneca Biopharma
  • 245. Sentien Biotechnologies
  • 246. Shandong Qilu Stem Cells Engineering
  • 247. Shenzhen Hornetcorn Biotechnology
  • 248. Stem Cell Medicine
  • 249. Stem Med
  • 250. STEMCELL Technologies
  • 251. StemCore
  • 252. Stemedica Cell Technologies
  • 253. Stemgenics
  • 254. Steminent Biotherapeutics
  • 255. Stemmatters
  • 256. Stemnovate
  • 257. Stempeutics Research
  • 258. Stryker
  • 259. Swiss Medica XXI Century
  • 260. System Bioscience
  • 261. Taiwan Bio Therapeutics
  • 262. Taiwan Human Disease iPSC Consortium
  • 263. Takara Bio
  • 264. Takara Bio
  • 265. Takeda
  • 266. Talaris Therapeutics
  • 267. Terumo
  • 268. The Emmes Company
  • 269. The University of California, Irvine
  • 270. The University California, San Diego
  • 271. The University Hospital of Dusseldorf
  • 272. The University of Wisconsin
  • 273. Thermo Fisher Scientific
  • 274. Tianhe Stem Cell Biotechnologies
  • 275. Tianjin Ever Union Biotechnology
  • 276. Tianjin Weikai Biological Engineering
  • 277. TICEBA
  • 278. Tocris Bioscience
  • 279. TreeFrog Therapeutics
  • 280. Turn Biotechnologies
  • 281. U.S. Stem Cell
  • 282. United Therapeutics
  • 283. Universal Cells
  • 284. University Medical Center Göttingen
  • 285. University of Bonn
  • 286. University of Cambridge
  • 287. University of Colorado
  • 288. University of Florida College of Medicine
  • 289. University of Helsinki
  • 290. University of Texas
  • 291. University of Utah
  • 292. University of Washington's Institute for Stem Cell and Regenerative Medicine
  • 293. University at Buffalo
  • 294. VcanBio Center for Translational Biotechnology
  • 295. Vericel
  • 296. VetStem
  • 297. ViaCyte
  • 298. Viscofan BioEngineering
  • 299. Waisman Biomanufacturing
  • 300. WuXi Advanced Therapies
  • 301. Yale Stem Cell Center
  • 302. YposKesi
目次

Example Insights:

Overview:

Over the years, advances in stem cell biology and regenerative medicine have enabled the discovery and development of a number of stem cell-based therapies. In fact, many believe that such interventions possess the potential to address several unmet needs related to the treatment of a wide range of diseases. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. However, challenges, such as scarcity of healthy stem cell donors, adverse immunological reactions upon treatment (owing to donor-recipient haplotype mismatches), and a number of ethical concerns related to the use of stem cells, are impeding progress in this field.

The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka's team in 2006 revolutionized stem cell research. Through his Nobel prize winning research, Yamanaka was able to reprogram mature somatic cells into a stem-like (pluripotent) state. This finding not only established the means to synthesize stem cells (thereby, offering a virtually endless supply of research material), but also provided the means to alleviate the social stigma surrounding stem cell research. Presently, cellular reprogramming is perceived as a powerful and versatile tool, with numerous applications in fundamental research and medicine. It is worth mentioning that, today, many experts believe that stem cell therapies may be a possible solution to the COVID-19 pandemic. In fact, there are speculations, based on some evidence, that infected patients treated with stem cells may be more likely to successfully combat the symptoms of the disease. Research has also demonstrated that mesenchymal stem cells have the potential to be effectively used to treat SARS-CoV-2 induced pneumonia. Numerous partnerships have been inked amongst stakeholders in this domain, indicative to future growth of the market. Interestingly, start-ups / university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

Scope of the Report:

The 'Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030' report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A review of the overall landscape of cell reprogramming market, featuring a list of over 30 cell reprogramming (iPSC Generation) / direct reprogramming service and product providers and a detailed analysis of these providers based on a number of parameters, such as year of establishment, company size, geographical location, location of manufacturing facilities, type of service (iPSC generation and direct reprogramming), type of offering (in-house development, kit, service, technology (for licensing) and iPSC lines), type of technology (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), type of vector used (viral vector, non-viral vector, mRNA and others), source cell for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), target indication(s), type of application (research and therapeutic) and additional service(s) offered (assay development, cell and tissue sourcing, cell banking, cell characterization, cell differentiation, cell sequencing, genome editing and other services).
  • An insightful competitiveness analysis of iPSC generation and direct reprogramming service providers, based on supplier strength (based on a company's employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation used, number of target indications and number of manufacturing facilities).
  • Elaborate profiles of the industry players that offer cell reprogramming services and products. Each profiles features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook.
  • A detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials.
  • An analysis of the partnerships that have been established in this domain since 2016, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • A list of stem cell therapy developers / manufacturers, generated based on a detailed analysis of a set of relevant parameters (such as company size (employee count), type of cell (s), indication count and existing partnership(s)), which are anticipated to partner with cell reprogramming service and product providers in the foreseen future.

One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Christiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics)
  • Julien Maruotti (Chief Scientific Officer, Phenocell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cell reprogramming (iPSC generation) / direct reprogramming service and products market and their likely evolution in the short-mid term and long term.

Chapter 3 provides a general overview of stem cell-based therapies, their classification and applications. In addition, it features a detailed discussion on cell reprogramming, including information on different cell reprogramming services. It provides information on the various cell reprogramming technologies available for the generation of iPSCs and their potential usability across different application areas. Further, the chapter includes a discussion on the key growth drivers and roadblocks to cell reprogramming.

Chapter 4 provides a review of the global cell reprogramming services and products market landscape. It includes information related to more than 30 players that are currently active in this domain. In addition, it features a detailed analysis of players based on the parameters, such as type of service, type of offering, type of technology offered, type of vector used, source cell for iPSC generation, target indication(s), type of application and type of additional service(s) offered. The chapter also highlights the academic players that provide stem cell reprogramming services and products. Furthermore, we have presented the contributions of various stakeholders that are developing affiliated products required for cell reprogramming.

Chapter 5 features an insightful competitiveness analysis of both iPSC generation and direct reprogramming service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (based on a company's employee count and years of experience) and service strength (which takes into account the number of reprogramming technologies offered, number of source cells used for iPSC generation, number of target indications and number of manufacturing facilities).

Chapter 6 provides elaborate profiles of all industry players that are currently engaged in the cell reprogramming domain. Each profile features a brief overview of the company, its financial information (if available), details on cell reprogramming approaches, types of cell(s) utilized and differentiated, target indication(s), other drug discovery services offered, recent developments and an informed future outlook.

Chapter 7 features a detailed analysis of the partnerships / collaborations that have been inked amongst the players in this market. It includes a brief description on the various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been adopted by stakeholders in this domain, and analysis on the trend of partnerships inked since 2016. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to cell reprogramming. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 provides a detailed analysis of more than 540 completed, ongoing and planned clinical studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, study design, current trial status, leading industry sponsors (in terms of number of trials conducted), study focus, type of stem cells, target indication(s), target therapeutic area(s), enrolled patient population and regional distribution of trials

Chapter 9 presents a list of stem cell therapy developers / manufacturers that are anticipated to partner with cell reprogramming service and product providers in the foreseen future. The list was prepared based on an in-depth analysis of potential stakeholders, taking into consideration multiple parameters, such as company size (employee count), type of cell (s), indication count and existing partnership(s).

Chapter 10 presents an insightful market forecast analysis, highlighting the likely growth of the cell reprogramming (iPSC generation) / direct reprogramming services and products market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cell for iPSC generation (fibroblast, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world).

Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Christiana Pires (Co-Founder and Chief Executive Officer, Asgard Therapeutics) and Julien Maruotti (Chief Scientific Officer, Phenocell).

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Stem Cells
    • 3.2.1. Classification of Stem Cells
      • 3.2.1.1. Based on Source of Stem Cell
      • 3.2.1.2. Based on Origin of Stem Cell
      • 3.2.1.3. Based on Potency of Stem Cell
    • 3.2.2. Routes of Administration of Stem Cell Therapies
    • 3.2.3. Applications of Stem Cell Therapies
  • 3.3. Introduction to Cell Reprogramming
    • 3.3.1. Cell Reprogramming Approaches and Affiliated Technologies
  • 3.4. Applications of Cell Reprogramming
  • 3.5. Key Growth Drivers and Constraints

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cell Reprogramming Service and Product Providers: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location
    • 4.2.4. Analysis by Location of Manufacturing Facilities
    • 4.2.5. Analysis by Type of Service
    • 4.2.6. Analysis by Type of Offering
    • 4.2.7. Analysis by Type of Technology
    • 4.2.8. Analysis by Vector Used
    • 4.2.9. Analysis by Source Cell for iPSC Generation
    • 4.2.10. Analysis by Target Indication
    • 4.2.11. Analysis by Application
    • 4.2.12. Analysis by Additional Service(s) Offered
  • 4.3. Cell Reprogramming Service and Product Providers: List of Non-Industry Players
    • 4.3.1. Analysis by Geographical Location
    • 4.3.2. Analysis by Type of Technology Used
    • 4.3.3. Analysis by Type of Vector Used
    • 4.3.4. Analysis by Source Cell for iPSC Generation
  • 4.3. Cell Reprogramming: List of Affiliated Products Providers

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Competitiveness Analysis: iPSC Generation Service and Product Providers
  • 5.5. Competitiveness Analysis: Direct Reprogramming Service and Product Providers

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Allele Biotechnology
    • 6.2.1. Company Overview
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. ALSTEM
    • 6.3.1. Company Overview
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. Applied Biological Materials
    • 6.4.1. Company Overview
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. Axol Bioscience
    • 6.5.1. Company Overview
    • 6.5.2. Recent Developments and Future Outlook
  • 6.6. Creative Bioarray
    • 6.6.1. Company Overview
      • 6.6.1.1. Recent Developments and Future Outlook
  • 6.7. DefiniGEN
    • 6.7.1. Company Overview
    • 6.7.2. Recent Developments and Future Outlook
  • 6.8. FUJIFILM Cellular Dynamics International
    • 6.8.1. Company Overview
    • 6.8.2. Recent Developments and Future Outlook
  • 6.9. Lonza
    • 6.9.1. Company Overview
    • 6.9.2. Recent Developments and Future Outlook
  • 6.10. Mogrify
    • 6.10.1. Company Overview
    • 6.10.2. Recent Developments and Future Outlook
  • 6.11. REPROCELL
    • 6.11.1. Company Overview
      • 6.11.1.1. Recent Developments and Future Outlook
  • 6.12. Stemnovate
    • 6.12.1. Company Overview
    • 6.12.2. Recent Developments and Future Outlook
  • 6.14. Thermo fisher Scientific
    • 6.14.1. Company Overview
      • 6.14.1.1. Recent Developments and Future Outlook

7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Stem Cell Therapies: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Trial Phase
    • 7.3.3. Analysis by Number of Patients Enrolled by Trial Registration Year
    • 7.3.4. Analysis by Study Design
    • 7.3.5. Analysis by Trial Recruitment Status
    • 7.3.6. Analysis by Sponsor / Collaborator
    • 7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
    • 7.3.8. Analysis by Trial Focus
    • 7.3.9. Analysis by Type of Stem Cell
    • 7.3.10. Analysis by Therapeutic Area
    • 7.3.11. Analysis by Type of Stem Cell and Therapeutic Area
    • 7.3.12. Geographical Analysis by Number of Clinical Trials
    • 7.3.13. Geographical Analysis by Trial Recruitment Status
    • 7.3.14. Geographical Analysis by Enrolled Patient Population

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Cell Reprogramming Services and Products Market: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year of Partnership and Type of Partner
    • 8.3.4. Analysis by Type of Partnership and Type of Partner
    • 8.3.5. Analysis by Type of Stem Cell
    • 8.3.6. Analysis by Target Therapeutic Area
    • 8.3.7. Analysis by Application
    • 8.3.8. Most Active Players: Analysis by Number of Partnerships
    • 8.3.9. Regional Analysis
    • 8.3.10. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNERSHIP OPPORTUNITIES

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Scoring Criteria and Key Assumptions
  • 9.4. Stem Cell Therapy Developers: Likely Partners for Cell Reprogramming Service and Product Providers
    • 9.4.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
    • 9.4.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
    • 9.4.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World
  • 9.5. Stem Cell Therapy Contract Manufacturers: Likely Partners for Cell Reprogramming Service and Product Providers
    • 9.5.1. Likely Partners for Cell Reprogramming Service and Product Providers in North America
    • 9.5.2. Likely Partners for Cell Reprogramming Service and Product Providers in Europe
    • 9.5.3. Likely Partners for Cell Reprogramming Service and Product Providers in Asia-Pacific and Rest of the World

10. MARKET FORECAST

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Forecast Methodology and Key Assumptions
  • 10.4. Global Cell Reprogramming Services and Products Market, 2020-2030
    • 10.4.1. Global Cell Reprogramming Services and Products Market: Distribution by Type of Technology, 2020-2030
      • 10.4.1.1. Cell Reprogramming Services and Products Market for Episomal Reprogramming, 2020-2030
      • 10.4.1.2. Cell Reprogramming Services and Products Market for mRNA Reprogramming, 2020-2030
      • 10.4.1.3. Cell Reprogramming Services and Products Market for Sendai Virus-based Reprogramming, 2020-2030
      • 10.4.1.4. Cell Reprogramming Services and Products Market for Other Reprogramming Technologies, 2020-2030
    • 10.4.2. Global Cell Reprogramming Services and Products Market: Distribution by Source Cell for iPSC Generation, 2020-2030
      • 10.4.2.1. Cell Reprogramming Services and Products Market for Fibroblasts, 2020-2030
      • 10.4.2.2. Cell Reprogramming Services and Products Market for Peripheral Blood Mononuclear Cells, 2020-2030
      • 10.4.2.3. Cell Reprogramming Services and Products Market for Unspecified Somatic Cells, 2020-2030
      • 10.4.2.4. Cell Reprogramming Services and Products Market for Other Cells, 2020-2030
    • 10.4.3. Global Cell Reprogramming Services and Products Market: Distribution by Application, 2020-2030
      • 10.4.3.1. Cell Reprogramming Services and Products Market for Research, 2020-2030
      • 10.4.3.2. Cell Reprogramming Services and Products Market for Therapeutic Use, 2020-2030
    • 10.4.4. Global Cell Reprogramming Services and Products Market: Distribution by Key Geographical Regions, 2020-2030
      • 10.4.4.1. Cell Reprogramming Services and Products Market in North America, 2020-2030
      • 10.4.4.2. Cell Reprogramming Services and Products Market in Europe, 2020-2030
      • 10.4.4.3. Cell Reprogramming Services and Products Market in Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS

  • 11.1. Chapter Overview
  • 11.2. Asgard Therapeutics
    • 11.2.1. Company Snapshot
    • 11.2.2. Christiana Pires, Co-Founder and Chief Executive Officer
  • 11.3. Phenocell
    • 11.3.1. Company Snapshot
    • 11.3.2. Interview Transcript: Julien Maruotti, Chief Scientific Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS